Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jan 25:2022:9556161.
doi: 10.1155/2022/9556161. eCollection 2022.

Efficacy and Safety of Endoscopic Submucosal Dissection for Dysplasia in Ulcerative Colitis Patients: A Systematic Review and Meta-Analysis

Qi-Shan Zeng  1 , Zhi-Jing Zhao  2 , Jiao Nie  3 , Min Zou  1 , Jia-Hui Yang  3 , Jin-Zhi Zhang  3 , Hua-Tian Gan  1   3
Affiliations
Review

Efficacy and Safety of Endoscopic Submucosal Dissection for Dysplasia in Ulcerative Colitis Patients: A Systematic Review and Meta-Analysis

Qi-Shan Zeng et al. Gastroenterol Res Pract. .

Abstract

Background and aims: Ulcerative colitis (UC) is associated with an increased risk of colorectal cancer. Current guidelines recommend endoscopic resection if the lesion is visible with distinct margins and a complete resection can be achieved. However, submucosal fibrosis due to chronic inflammation may increase the procedural risk and reduce the complete resection rate. The aim of this study is to assess the efficacy and safety of endoscopic submucosal dissection (ESD) for dysplasia in UC patients.

Materials and methods: A systematic search of databases was performed until May 30, 2021. Studies that reported the resection rates and complication rates of ESD for dysplasia in UC patients were included. A random-effects model was used to generate conservative estimates of the prevalence of the outcome variables. All data analyses were performed using software Stata (version 15).

Results: 8 studies were enrolled in the meta-analysis, with a total of 203 dysplastic lesions in 192 UC patients. The mean lesion size was 26.7 mm. About 83% of the lesions were located in the left-side colon, and 90% of the lesions were nonpolypoid, and about 71% of the lesions had submucosal fibrosis. The mean procedural time of ESD was 83 minutes. The en bloc resection rate, complete resection rate, and curative resection rate were 94%, 84%, and 81%, respectively, with a local recurrence rate of 5%. The pooled prevalence of bleeding and perforation were 8% and 6%, respectively. The rates of metachronous tumors and additional surgery after ESD were 6% and 10%, respectively.

Conclusion: Despite some limitations, our study suggests that ESD is an effective and safe treatment for dysplasia in UC patients. However, randomized controlled multicenter studies with less heterogeneity and longer follow-up are needed to better assess the clinical outcomes of ESD in UC patients.

PubMed Disclaimer

Conflict of interest statement

The authors declare that there is no conflict of interest regarding the publication of this paper.

Figures

Figure 1
Figure 1
Flow diagram of the studies included in this meta-analysis.
Figure 2
Figure 2
Resection rates and pooled estimates of endoscopic submucosal dissection.
Figure 3
Figure 3
Prevalence of complications and pooled estimates of endoscopic submucosal dissection.
Figure 4
Figure 4
Prevalence of metachronous tumors and additional surgery after endoscopic submucosal dissection.
See this image and copyright information in PMC

References

    1. Molodecky N. A., Soon I. S., Rabi D. M., et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology . 2012;142(1):46–54.e42. doi: 10.1053/j.gastro.2011.10.001. - DOI - PubMed
    1. Eaden J. A., Abrams K. R., Mayberry J. F. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut . 2001;48(4):526–535. doi: 10.1136/gut.48.4.526. - DOI - PMC - PubMed
    1. Jess T., Rungoe C., Peyrin–Biroulet L. Risk of colorectal cancer in patients with ulcerative colitis: a meta-analysis of population-based cohort studies. Clinical Gastroenterology and Hepatology . 2012;10(6):639–645. doi: 10.1016/j.cgh.2012.01.010. - DOI - PubMed
    1. Mescoli C., Albertoni L., D’incá R., Rugge M. Dysplasia in inflammatory bowel diseases. Digestive and Liver Disease . 2013;45(3):186–194. doi: 10.1016/j.dld.2012.07.013. - DOI - PubMed
    1. Annese V., Beaugerie L., Egan L., et al. European evidence-based consensus: inflammatory bowel disease and malignancies. Journal of Crohn's & Colitis . 2015;9(11):945–965. doi: 10.1093/ecco-jcc/jjv141. - DOI - PubMed